Skip to content

Study · Animal study (in vivo) · mouse · 2005

3 results

The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury.

Gozes I, Zaltzman R, Hauser J, Brenneman DE, Shohami E, Hill JM

Current Alzheimer research1 Apr 2005Cited by 44 (Europe PMC)

PMID15974912 (opens in a new tab)DOI10.2174/1567205053585873 (opens in a new tab)PepBankPUB-15974912
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with head trauma, prophylactic or curative NAP treatment indicated improvement in longitudinal clinical, biochemical and anatomical outcomes.

    In plain wordsIn mice with head trauma, preventive or curative NAP treatment indicated improvement in clinical, biochemical and anatomical outcomes.

    Peptide
    Davunetide
    Outcome
    IncreaseLongitudinal clinical, biochemical and anatomical outcomes
    Study

    mousen: not reported in source

    Mouse head trauma model
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the mouse model, NAP treatment (prophylactic or curative) indicated improvement in longitudinal clinical, biochemical and anatomical outcomes.
    1 context sentence
    Summary · context
    To further evaluate the in vivo efficacy of NAP neuroprotection we used a mouse model of head trauma; a condition that presents a risk factor for the development of Alzheimer's disease in injured patients.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In mice with closed head injury, NAP treatment decreased injury-associated Mac-1 expression at the injury site.

    In plain wordsIn mice with head injury, NAP treatment decreased injury-associated Mac-1 expression at the injury site.

    Peptide
    Davunetide
    Outcome
    DecreaseMac-1 expression at injury site
    Study

    mousen: not reported in source

    Mouse head trauma model
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, closed head injury was associated with a delayed increase in the expression of the immune cell surface glycoprotein Mac-1 (CD11B antigen) at the injury site that was decreased in NAP-treated mice.
    1 context sentence
    Summary · context
    To further evaluate the in vivo efficacy of NAP neuroprotection we used a mouse model of head trauma; a condition that presents a risk factor for the development of Alzheimer's disease in injured patients.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In Mac-1-deficient mice, NAP protection against adverse clinical outcome coincided with increased Mac-1 transcripts in Mac-1-expressing mice.

    In plain wordsIn Mac-1-deficient mice, NAP protected against adverse clinical outcome during the reported period.

    Peptide
    Davunetide
    Outcome
    DecreaseAdverse clinical outcome in Mac-1-deficient mice
    Study

    mousen: not reported in source

    Mac-1-deficient mice with head injury
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NAP protection in Mac-1-deficient mice against adverse clinical outcome was concomitant with the time period when increases in Mac-1 transcripts were observed in the Mac-1 expressing mice ( approximately four weeks after the injury).
    1 context sentence
    Summary · context
    To further evaluate the in vivo efficacy of NAP neuroprotection we used a mouse model of head trauma; a condition that presents a risk factor for the development of Alzheimer's disease in injured patients.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.